FDA Issues EUA for COVID-19 Convalescent Plasma
FDA issued an emergency use authorization for COVID-19 convalescent plasma treatments following a report on NIH concerns about insufficient studies and data.
On Aug. 23, 2020, FDA issued an emergency use authorization (EUA) for investigational COVID-19 convalescent plasma (CCP) for the treatment of COVID-19 in hospitalized patients, noting in a clinical memorandum that “current data for the use of CCP in adult hospitalized patients with COVID-19 supports the conclusion that CCP meets the ‘may be effective’ criterion for issuance of an EUA.”
The author of the FDA memo, whose name was redacted in the released version of the document, concluded, “It is reasonable to conclude that the known and potential benefits of CCP outweigh the known and potential risks of CCP for the proposed EUA. Current data suggest the largest clinical benefit is associated with high-titer units of CCP administered early in the course of disease.”
The memo also stated the need for “adequate and well-controlled randomized trials” to demonstrate CCP efficacy, determine the optimal product attributes, and identify the patient populations suitable for use.
In making the EUA decision, FDA analyzed safety and efficacy data from a National Expanded Access Treatment Protocol (EAP) program initiated by the Mayo Clinic in April 2020. More than 70,000 patients have been treated with CCP.
In an Aug. 23, 2020 press conference, FDA reported that, “Based on an evaluation of the EUA criteria and the totality of the available scientific evidence, the FDA’s Center for Biologics Evaluation and Research determined that the statutory criteria for issuing an EUA criteria were met.”
The agency further noted, “it is reasonable to believe that COVID-19 convalescent plasma may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitalized patients.”
The announcement made by President Donald Trump at a White House press event on Aug. 23, 2020 was met with criticism by medical professionals concerned that the about insufficient randomized controlled clinical trials and the politicization of FDA decision making. In an Aug. 19, 2020 article, the New York Times reported the leading government scientists from the National Institutes of Health warned that data from the Mayo Clinic study were not strong enough to merit an emergency authorization. On Aug. 22, the President expressed his displeasure at the lack of action in a Tweet, suggesting the delay was politically motivated.
Source:
FDA Issues EUA for COVID-19 Convalescent PlasmaFDA Clinical Memo
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
